



MELACYTE ® (erlotinib) is approved as a first-line treatment, maintenance treatment, and 2nd- or 3rd-line treatment for advanced-stage non-small cell lung cancer (NSCLC). MELACYTE ® (erlotinib) is prescribed as initial treatment for patients with NSCLC whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. (First-line treatment),

MELACYTE ® (erlotinib) is prescribed as maintenance treatment for advanced-stage NSCLC in patients whose cancer has not spread or grown after prior treatment with certain types of chemotherapy.

MELACYTE ® (erlotinib) is prescribed as 2nd- or 3rd-line treatment for advanced-stage NSCLC in patients whose cancer has spread or grown after receiving at least one round of chemotherapy.

MELACYTE ® (erlotinib) is not meant to be used at the same time as certain types of chemotherapy for advanced NSCLC. For initial treatment of patients with NSCLC whose cancer has spread to other parts of the body, it is not known if MELACYTE ® (erlotinib) is safe and effective in other EGFR mutations.

MELACYTE ® (erlotinib) is approved for advanced-stage pancreatic cancer.

MELACYTE ® (erlotinib) in combination with gemcitabine is prescribed for patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.

What should I do if I am taking or am prescribed other medicines or supplements while taking MELACYTE ® (erlotinib)? It is important to tell your HCP about all of the medicines and herbal supplements you are taking.

DO NOT start taking any new medicines or herbal supplements before talking with your HCP.

DO NOT eat grapefruit or drink grapefruit juice while taking MELACYTE ® (erlotinib), except under the care of your HCP.